Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Robotic Partial Nephrectomy for Large Renal Masses

BJU Int; ePub 2018 Jan 22; Delto, Paulucci, et al

Robotic partial nephrectomy appears to be a reasonable option for certain renal masses, provided that an experienced surgeon performs the procedure at a center that can manage postoperative complications, researchers concluded after conducting an analysis involving nearly 1,800 individuals. Participants had cT1a (n=1358), cT1b (n=379), or cT2a (n=41) renal masses. Investigators looked at how intra and postoperative outcomes in patients with cT2a masses compared to those with the other 2 mass types. Among the results:

  • Performing robotic surgery on cT2a vs cT1a masses resulted in a 12% longer operative time, 32% increase in estimated blood loss, 7% increase in ischemia time, nearly 4-fold higher odds of acute kidney injury at discharge, and a nearly 11-fold higher recurrence risk.
  • Performing the procedure on cT2a vs cT1b masses resulted in a 12% increase in blood loss.
  • Operative time and recurrence risk were not statistically different.
  • Complications, positive margins, length of stay, and renal function decline up to 2 years post-procedure were not statistically different.


Delto J, Paulucci D, Helbig M, et al. Robotic partial nephrectomy for large renal masses: A multi-institutional series. [Published online ahead of print January 22, 2018]. BJU Int. doi:10.1111/bju.14139.

This Week's Must Reads

Flat pricing of ibrutinib , Sales revenues at the potential expense of patient safety

Most oncologists discuss medical marijuana with patients, Braun I et al. J Clin Oncol. 2018 May 10. doi: 10.1200/JCO.2017.76.1221.

$800M cut proposed for Centers for Medicare & Medicaid Innovation, Proposed rescission of budget authority

Medicare Beneficiary Identifiers required for billing by 2019, New Medicare cards

Trump administration unveils drug pricing initiative, American Patients First

Must Reads in Renal Cell Carcinoma

miRNAs are biomarkers for RCC prognosis, Pan X et al. Biomedicine and Pharmacotherapy 102: 2018; 718-27.

Pseudocapsule status predicts RCC prognosis, Xi W et al. The Journal of Urology 199: 2018; 915-20.

New model uses histologic subtypes to predict RCC prognosis, Leibovich B et al. European Urology 73; 2018: 772-80.

Histologic similarities in clear cell papillary RCC and tuberous sclerosis, Williamson S et al. Human Pathology 75; 2018: 10-15

IMDC risk group classification predicts sunitinib response, Rini B et al. Clinical Genitourinary Cancer; published online May 4, 2018